• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Topical pimecrolimus use for atopic dermatitis not linked to malignancy

byShirin BajajandAdam Whittington
February 26, 2015
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Contrary to previous information, pimecrolimus was not associated with lymphomas or cutaneous malignancies.

Evidence Rating Level: 2 (Good)

Study Rundown: Atopic dermatitis (AD), an inflammatory disease of the skin, necessitates a variety of treatment options due to its high prevalence and possibly severe symptoms. Calcineurin inhibitors are one class of medication that can treat AD. However, some drug members of this family have been associated with increased risk of malignancy as an adverse effect. These authors sought to understand the risk of malignancy associated with pimecrolimus, a calcineurin inhibitor. Authors observed that usage of topical pimecrolimus in the treatment of AD was not associated with increased risk of malignancy. While a large number of participants were statistically analyzed through the Pediatric Eczema Elective Registry (PEER), participants may not have reported side effects due to loss of follow-up; however, the authors attempted to contact this group.

Click to read the study in JAMA Dermatology

Relevant Reading: Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice

In-Depth [prospective cohort]: This study sought to understand the association between topical use of pimecrolimus in AD and malignancy risk utilizing 7,457 children, a total of 26,792 person years. The PEER was used to identify and to evaluate patients with mild to moderate AD who were between the ages of 2 and 17. Participants had used pimecrolimus cream for at least 6 weeks out of the preceding half year and were contacted every 6 months regarding malignancy after usage of pimecrolimus. Incidence rates of cancer were compared to the Surveillance, Epidemiology and End Results (SEER) program rates. Authors found that five malignancies (2 leukemias, 1 osteosarcoma, and 2 lymphomas) had been reported. However, the standardized incidence ratio for all malignancies (1.2, 95% CI, 0.5-2.8) as well as the aforementioned malignancies were not statistically significant.

Image: CC/Wiki/Eisfelder

RELATED REPORTS

Severe atopic dermatitis associated with symptoms of depression and internalizing behaviors in children

#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis

#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dermatitis
Previous Post

Ultrasound-accelerated thrombolysis may improve pulmonary embolism outcomes

Next Post

Long-term androgen deprivation may improve survival in prostate cancer

RelatedReports

Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Dermatology

Severe atopic dermatitis associated with symptoms of depression and internalizing behaviors in children

September 6, 2021
#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis
StudyGraphics

#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis

August 26, 2021
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;

June 24, 2021
#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy
StudyGraphics

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

June 10, 2021
Next Post
Testosterone and estrogen exert independent effects in the pathogenesis of male hypogonadism

Long-term androgen deprivation may improve survival in prostate cancer

Hand dishwashing linked to fewer allergies in children

Hand dishwashing linked to fewer allergies in children

AAP recommends focus on nutrient-rich foods in schools

AAP recommends focus on nutrient-rich foods in schools

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options